Healthy Skepticism Library item: 4798
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
 
Publication type: Journal Article
Citrome L, Jaffe A, Levine J, Lindenmayer JP.
Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies.
J Clin Psychiatry 2005 Dec; 66:(12):1512-6
http://article.psychiatrist.com/?ContentType=START&ID=10002270
Abstract:
BACKGROUND: A substantial number of patients with psychosis receive quetiapine in amounts that are greater than what is recommended in the product labeling approved by drug regulatory agencies. The purpose of this article is to review the past and present dosing patterns of quetiapine for the treatment of schizophrenia. METHOD: A PubMed search for the period January 1, 1990, to July 1, 2005, was conducted to identify English-language articles related to quetiapine dose in schizophrenia using the search terms quetiapine, dose, and schizophrenia. Trends in dosing of quetiapine in a large, state-operated psychiatric hospital system and the anecdotal evidence describing the use of quetiapine in excess of 800 mg/day were also reviewed. RESULTS: The registration studies of quetiapine suggest a target dose range of 300 to 500 mg/day for schizophrenia. In contrast, among inpatients hospitalized in New York State in the period of April 1, 2004, to June 30, 2004, the mean dose of quetiapine prescribed was 620 mg/day, with 33.6% receiving doses in excess of 750 mg/day. Patients with nonwhite ethnicity, length of stay of at least 1 year, or history of prior state hospital admission were more likely to receive doses greater than 750 mg/day. Patients receiving quetiapine as antipsychotic monotherapy or in combination with other antipsychotics were equally likely to receive doses greater than 750 mg/day. Published anecdotal reports describe the use of quetiapine in excess of 800 mg/day and up to 2400 mg/day among patients not responding to lower doses, but currently there are no published reports from double-blind randomized clinical trials establishing the utility of this high-dose treatment strategy. CONCLUSIONS: Dosing of quetiapine in clinical practice is higher than what has been established in the registration program for schizophrenia. Although there is anecdotal evidence describing the use of quetiapine in excess of 800 mg/day, double-blind randomized clinical trials are needed.
Keywords:
Antipsychotic Agents/administration & dosage*
Antipsychotic Agents/therapeutic use
Comparative Study
Dibenzothiazepines/administration & dosage*
Dibenzothiazepines/therapeutic use
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Labeling/standards
Drug Therapy, Combination
Drug Utilization/statistics & numerical data
Drug and Narcotic Control
Female
Hospitalization/statistics & numerical data
Hospitals, Psychiatric/statistics & numerical data
Humans
Male
Placebos
Prescriptions, Drug/statistics & numerical data
Randomized Controlled Trials
Research Design/statistics & numerical data
Research Support, Non-U.S. Gov't
Schizophrenia/drug therapy*